Aiolos Bio
San Francisco
About Aiolos Bio
Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $245.0M
- Funding stage: M&A
- Last round: Series A (Oct 2023)
- Website: aiolosbio.com
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/aiolos-bio-77609 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.